Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Synergy Pharmaceuticals Surges as Investors Await Data

Synergy Pharmaceuticals Inc., a developer of drugs for gastrointestinal disorders, increased the most in a year on investor optimism that its experimental treatment for irritable bowel syndrome may have helped patients in a study.

Synergy gained 11 percent to $4.89 at the close in New York. The shares of the New York-based company increased 3.3 percent in the past 12 months.

Data from a mid-stage trial of the drug known as plecanatide may be released by the end of this month, according to Irina Rivkind, an analyst with Cantor Fitzgerald LP in New York. The medicine, if approved, is expected to compete with Ironwood Pharmaceuticals Inc.’s Linzess that is “projected to be a blockbuster drug,” Rivkind said in an e-mail. Both medicines help irritable bowel syndrome patients with constipation and chronic idiopathic constipation.

“Plecanatide is the key asset for Synergy,” Rivkind said. Depending on the results “we think Synergy could be acquired by a larger company,” she said.

The company didn’t immediately return a telephone call seeking comment on the share movement.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.